Cidara治疗 CDTX 深 沪
已收盘 08-08 16:00:00 美东时间
62.00
+0.270
+0.44%
华盛通- 最 高62.3752
- 今 开57.79
- 成交量 42.48万股
- 最 低 56.53
- 昨 收 61.73
- 总市值 8.04亿
- 52周最高 66.945
- 市盈率 静 --
- 换手率 3.28%
- 52周最低 10.14
- 委 比 -83.07%
- 总股本 1296.98万
- 历史最高 382.60
- 量 比 1.21
- 振 幅 9.47%
- 历史最低 8.00
- 每 手 1
- 风险率 2.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HC Wainwright & Co. Maintains Buy on Cidara Therapeutics, Raises Price Target to $74
HC Wainwright & Co. analyst Sara Nik maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target from $53 to $74.
08-08 18:51
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025
Cidara Therapeutics, a biotechnology company, will release its Q2 2025 financial results and operational highlights on August 7, 2025, after market close. A conference call and webcast will be held at 5:00 PM Eastern Time to discuss the results and business updates. Cidara Therapeutics uses its Cloudbreak® platform to develop drug-Fc conjugate immunotherapies, with CD388 as its lead candidate targeting influenza prevention. For more details, visi...
07-24 12:00
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cidara Therapeutics granted 12,100 shares of stock options and RSUs to two new employees under its 2020 Inducement Incentive Plan, with a grant date of June 30, 2025. The stock option has an exercise price of $48.71 per share, vesting over four years, and RSUs vest in four annual installments. The awards are subject to continuous service and plan terms. The company uses its Cloudbreak® platform to develop drug-Fc conjugates (DFCs) for antiviral a...
07-01 20:59
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
JMP Securities Maintains Market Outperform on Cidara Therapeutics, Maintains $59 Price Target
JMP Securities analyst Roy Buchanan maintains Cidara Therapeutics (NASDAQ:CDTX) with a Market Outperform and maintains $59 price target.
06-30 21:06
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
Cidara Therapeutics, Inc. has been added to the Russell 2000 and Russell 3000 Indexes, marking a significant achievement for the biotech company. CEO Jeffrey Stein highlighted the inclusion as a validation of the company's progress, following positive Phase 2b trial results and successful $400 million financing. Cidara leverages its Cloudbreak platform to develop drug-Fc conjugates, with CD388 targeting universal influenza prevention and CBO421 f...
06-30 12:00
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Cidara Therapeutics completed an underwritten public offering of 9,147,727 shares, raising $402.5 million. J.P. Morgan, Morgan Stanley, Guggenheim, and Cantor were joint bookrunners. The company uses its Cloudbreak platform to develop DFC therapeutics, with CD388 (anti-influenza) and CBO421 (anti-CD73 for solid tumors) as key candidates.
06-26 21:15
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
